作者: Debabrata Mukherjee , David J. Moliterno
关键词:
摘要: Platelet function tests may measure different aspects of platelet function, which include adherence, activation, aggregation and secretion. The goal testing in the catheterization lab is to provide information about contributions risk thrombotic or hemorrhagic events optimization anti-platelet therapy for percutaneous interventions (PCI). Important clinical questions prior coronary are whether an antiplatelet agent having desired effect on inhibition (ef~cacy) patient has suf~cient residual avoid bleeding (safety). role aspirin thienopyridines well established management artery disease setting interventions. last several years have demonstrated unequivocal ef~cacy intravenously administered GPIIb/IIIa antagonists acute syndromes Twenty-~ve ago, important insight into molecular basis was provided by discovery that two major membrane glycoprotein bands, GPII GPIII were missing from surface thrombasthenic platelets [1]. To date, more than 60,000 patients with ischemic heart been treated trials a new class potent highly effective agents, speci~cally targeting this IIb/IIIa receptor [2]. Three such drugs licensed US Food Drug Administration, many phase II III potentially expanding series indications. Four parenterally (abciximab, epti~batide, tiro~ban lami~ban) tested indications, syndromes. show drug effect, all agents reducing events.